Lactate dehydrogenase-to-albumin ratio studied in Chinese patients with IgA nephropathy

This retrospective cohort study investigated the lactate dehydrogenase-to-albumin ratio (LAR) in 1,276 Chinese patients with biopsy-proven immunoglobulin A nephropathy (IgAN). The analysis compared patients with high LAR (≥4.05) to those with low LAR (<4.05) to assess potential associations with clinicopathologic changes and disease prognosis. The study setting, follow-up duration, and specific primary outcome were not reported in the provided data.

No specific numerical results, effect sizes, absolute numbers, or statistical measures (p-values or confidence intervals) were reported for the main outcomes. The direction of any associations between LAR and clinicopathologic changes or disease prognosis was also not specified in the available evidence.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, were not reported. The key limitation acknowledged is the retrospective study design, which prevents causal inference. Funding sources and conflicts of interest were not reported.

In clinical practice, these findings represent an early, hypothesis-generating observation about a potential biomarker ratio in a specific patient population. The retrospective nature and lack of reported outcome data mean this evidence cannot yet inform clinical decision-making. Further prospective research with clearly defined endpoints is needed to determine whether LAR has any utility in predicting IgAN progression.